iifl-logo

Gland Pharma Ltd Historical Data

Add as a Preferred Source on Google
2,262.2
(-1.92%)
Jun 12, 2026|05:30:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Gland Pharma Ltd Historical Data

13/05/2026calendar-icon
13/06/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

13-May-2026

1,870

1,872.11,8131,844.213,37618,37,61,697.443,738

14-May-2026

1,844.2

1,9061,822.21,898.210,57532,84,50,469.11,08,947

15-May-2026

1,910.1

1,9501,853.61,868.314,22126,53,08,090.387,847

18-May-2026

2,122

2,2072,0342,156.63,94,98815,16,51,49,252.813,05,239

19-May-2026

2,148

2,273.92,138.52,251.11,49,2005,27,15,26,194.96,29,504

20-May-2026

2,232.9

2,295.12,201.92,221.864,7852,64,82,66,248.93,88,586

21-May-2026

2,230

2,3702,2302,33157,3842,34,42,86,232.75,34,050

22-May-2026

2,353.5

2,363.52,307.22,33438,3992,01,79,76,644.75,17,461

25-May-2026

2,369.8

2,3962,321.12,333.841,4261,19,26,61,0152,09,176

26-May-2026

2,339.7

2,354.72,252.12,307.944,1672,02,08,09,210.75,87,252

27-May-2026

2,324.1

2,354.72,309.22,31320,65352,14,87,758.21,21,231

29-May-2026

2,315

2,337.52,2302,25022,89749,89,23,074.91,14,902

01-Jun-2026

2,278.6

2,356.52,255.82,292.449,0701,35,26,61,817.52,74,419

02-Jun-2026

2,268.9

2,337.52,263.22,27731,5751,10,67,14,827.33,01,994

03-Jun-2026

2,277

2,305.92,2222,232.321,60057,82,87,203.51,25,012

04-Jun-2026

2,221.2

2,276.72,2122,219.527,63945,75,32,260.798,665

05-Jun-2026

2,232.8

2,288.32,1962,27343,9921,11,15,92,468.12,14,704

08-Jun-2026

2,269.1

2,3362,2372,247.841,0551,08,60,64,933.11,53,648

09-Jun-2026

2,257

2,314.92,256.92,288.532,5931,19,48,11,0103,15,056

10-Jun-2026

2,299

2,341.52,2502,267.825,37173,69,70,380.91,35,858

11-Jun-2026

2,243

2,3952,215.42,306.51,72,0375,66,35,08,797.99,56,196

12-Jun-2026

2,311.5

2,3542,2502,262.254,4191,59,30,83,908.93,23,767

Gland Pharma: Related NEWS

Gland Pharma Stock Gains 7% as Q3 Revenue Climbs 22.5% to ₹1,695.3 Crore

The European business reported a 54 percent year on year surge in topline during the quarter.

29 Jan 2026|12:20 PM
Read More
Top Stocks for Today - 8th January 2026

Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.

8 Jan 2026|07:31 AM
Read More
Top Stocks for Today - 4th November 2025

Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.

4 Nov 2025|08:01 AM
Read More
Top Stocks for Today - 14th July 2025

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.

14 Jul 2025|06:30 AM
Read More
Gland Pharma Gets USFDA Clearance for Visakhapatnam Facility

The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.

25 Jun 2025|12:07 PM
Read More
Top Stocks for Today - 5th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.

5 Jun 2025|07:53 AM
Read More
Gland Pharma gets USFDA approval for blood pressure drug

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

4 Jun 2025|03:34 PM
Read More
Gland Pharma Q4 Net Profit Declines 3.1% to ₹186.5 Crore; Revenue Down 7.3% YoY

Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.

22 May 2025|08:49 AM
Read More
Gland Pharma Gets USFDA Nod for Glaucoma Drug

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

30 Apr 2025|03:40 PM
Read More
USFDA Issues Three Observations to Gland Pharma's Visakhapatnam Facility

The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.

26 Feb 2025|12:22 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.